January 18, 2022: We support the “I” recommendation against screening for either prediabetes or type 2 diabetes in asymptomatic children aged 18 years or younger.
Read More »On Medical Treatments & Products
Statement of Dr. Diana Zuckerman Regarding the January 11, 2022 CMS Decision about Aduhelm
January 11, 2022: Dr. Diana Zuckerman, president of NCHR, speaks in favor of CMS decision to limit coverage of the Alzheimer’s drug, Aduhelm.
Read More »NCHR’s Testimony to FDA on Bardoxolone for Kidney Failure from Alport Syndrome
December 8, 2021: We agree with FDA scientists that bardoxolone does not demonstrate effectiveness at slowing the loss of kidney function and reducing the risk of progression to kidney failure, which are the outcomes that matter most to patients.
Read More »NCHR’s Testimony to FDA About Molnupiravir for COVID-19
November 30, 2021: For molnupiravir, the balance of benefits and risks may differ between different types of patients, and not all types of patients were studied.
Read More »NCHR Comments on USPSTF’s Draft Recommendation on Aspirin Use to Prevent Cardiovascular Disease
November 8, 2021. Based on the data, we strongly support the “C” grade recommendation for patients 40 to 59 years old with a 10% or more risk of developing CVD, as well as the “D” grade recommendation for patients 60 and older. However, we urge the USPSTF to include additional information to their recommendation.
Read More »